Articles tagged with Drug Development
Researchers found no link between R&D costs and high drug prices in the US, contradicting industry claims. Despite $83 billion spent on R&D in 2019, drug prices are driven by market demand rather than investment costs.
A $1 million NIH grant will help MU researchers analyze the effectiveness of a HIPAA-secure text messaging platform in nursing homes. The study aims to improve quality of care and prevent costly hospital transfers by speeding up decision-making.
Monon Bioventures has received a grant to develop a novel glioblastoma treatment using armed natural killer cells. The treatment, created by Purdue University researcher Sandro Matosevic, shows promise in preclinical proof of concept and aims to manufacture the therapeutic for clinical studies.
Researchers at UMC Utrecht will investigate how intestinal microbiota impacts cancer immunotherapy and therapy side effects. The project aims to develop microbiota-targeted therapies to improve ICI treatment effectiveness and reduce severe inflammation.
Researchers discovered that autophagy facilitates the elimination of cancer cells via cell competition, highlighting its potential as a target for cancer prevention and treatment. The study sheds light on the role of autophagy in maintaining tissue homeostasis and opening avenues for novel anti-cancer therapeutics.
The Critical Path Institute (C-Path) has established a public-private partnership with the FDA and NIH to advance treatments for rare neurodegenerative diseases. The partnership will leverage C-Path's expertise in data management, quantitative analytics, and regulatory science to accelerate medical product development.
In a Phase I/II trial, selpercatinib demonstrated a 44% objective response rate across multiple tumor types, including pancreatic and colorectal cancers. The study found responses regardless of cancer type or prior treatment history, confirming RET fusions as a tissue-agnostic target.
Scientists at SLAC National Accelerator Laboratory have seen the critical interaction between SARS-CoV-2 protein Mpro and human immune system protein NEMO. The study reveals that Mpro can cut NEMO, slowing down the immune response and allowing the virus to evade the body.
A newly identified link between chronic pain and lung cancer in mice suggests that old drugs such as clonidine, capsaicin, and fluphenazine may offer new treatments for chronic pain. The study found that blocking the BH4 pathway reduced pain sensitivity and decreased tumor growth in mouse models of KRAS-driven lung cancer.
A new study suggests that the nuclear receptor TLX can inhibit the growth and progression of triple-negative breast cancer. TLX+ cells showed lower tumor growth, migration, and invasion rates compared to those without TLX expression.
Recent studies in Journal of Pharmaceutical Analysis highlight innovative nanosensors for efficient biomolecular detection, including rutin, paracetamol, and hypochlorite. These advancements enable high sensitivity and reliability in clinical samples, paving the way for improved patient care.
Researchers have identified dry voids in G protein-coupled receptors that are crucial for their activation and transmit signals to the cell interior. These unique binding sites differ among subclasses and offer a promising route for developing targeted therapies with fewer side effects.
Rice University researchers have developed a treatment combining drug factory implants producing interleukin-2 with checkpoint inhibitors to eradicate advanced-stage mesothelioma tumors in mice. The treatment resulted in complete tumor destruction in all seven treated mice, offering a promising approach to this aggressive lung cancer.
Researchers at Terasaki Institute create micro-organospheres for direct viral infection, immune cell penetration, and high-throughput therapeutic drug screening. The technology holds promise for personalized medicine, tumor therapy and rapid drug testing.
A new gene variant, MFGE8, has been discovered that protects against coronary heart disease, with carriers experiencing a one-fifth lower risk. The variant is located in the MFGE8 gene and inhibits the function of lactadherin protein, which affects arterial stiffness.
A recent study published in Cancer Research identified a unique vulnerability in certain high-risk cancers that can be exploited for targeted therapy. Researchers found that cancer cells with alternative lengthening of telomeres (ALT) have a common weakness, leading to resistance to DNA-damaging agents and chemotherapy.
Researchers at NTNU have developed a digital system called Drugvirus.info that can identify the most effective medicinal mix against viruses, reducing development time from years to months. This approach could lead to the creation of new treatments for 200 viral diseases, saving millions of euros and lives.
Researchers at Weill Cornell Medicine found that disrupting circadian clocks leads to increased fat cell growth and insulin production. Stress and other factors can throw the body's 'clocks' out of rhythm, contributing to weight gain.
Researchers identified CUDC907 as a dual phosphoinositide-3 kinase/histone deacetylase inhibitor that promotes apoptosis in NF2 schwannoma cells. The compound reduced viability and induced cell cycle arrest in human merlin deficient Schwann cell models.
Researchers developed a mathematical model to predict the efficiency of nanoparticle delivery into cells, particularly in stem cells. They found that nanoparticles become trapped in bubble-like vesicles, preventing them from reaching their targets.
MU researchers have identified specific mutations in the Omicron variant's spike protein that help it evade existing antibodies from vaccines or previous COVID-19 infections. These findings can inform developers of COVID-19 treatments and vaccines, which may need to target different parts of the virus to produce effective outcomes.
A new report highlights the importance of acknowledging antimicrobial resistance (AMR) in regulatory frameworks for accelerated drug approval. The analysis provides recommendations to improve access to new antibiotics in Brazil, India, and South Africa, where antibiotic development is hampered by regulatory hurdles.
The WHO advises against the use of colchicine and fluvoxamine for treating non-severe COVID-19, citing insufficient evidence and potential harms. No recommendation is made for these drugs in patients with severe or critical illness.
Researchers at Aarhus University have developed an easy and inexpensive method for linking molecules to DNA sequences with desired functions. The method uses sulfonyl azides to introduce various functionalities, avoiding the need for expensive and unstable special phosphoramidites.
Indiana University researchers are using a mouse model to study the effects of cannabis use during adolescence, which could impair working memory and increase the risk of psychosis later in life. The $2M NIH grant aims to develop therapies to treat adverse effects.
Researchers from PSI, EPFL, and the University of Geneva developed a new method to distinguish between mirror-image molecules using helical dichroism. This approach provides stronger signals compared to circular dichroism (CD), which is widely used but has weak signals suitable only for gas-phase samples.
A new classification system for colorectal cancer has been proposed, grouping cancers into five subtypes based on epithelial status, microsatellite status, and fibrosis. This update could inform targeted drug development efforts and improve treatment approaches for patients with different biological characteristics.
Research finds that cannabis users have a significantly higher risk of emergency room visits and hospital admissions for any cause. However, the study did not find a significant link between cannabis use and respiratory health issues. The authors conclude that further research is needed to confirm their findings.
Researchers elucidated the molecular mechanisms of acetylcholine in learning and memory, revealing a signaling cascade involving protein kinase C. The study opens doors to new therapeutic strategies for Alzheimer's disease.
Researchers at Karolinska Institutet have improved the ability of a protein to repair oxidative DNA damage, creating a new drug development concept. The technique can lead to improved treatments for diseases involving oxidative stress.
Researchers at the University of New Hampshire have found that a repurposed drug compound can inhibit the activity of SARS-CoV-2's main protease enzyme. This breakthrough could lead to new treatments and slow the spread of COVID-19, an RNA virus known for causing seasonal epidemics.
Researchers found that 27.8% of drugs with high abuse potential successfully completed development compared to 4.7% for low-abuse potential drugs. Funding is needed to improve understanding of pain mechanisms and develop non-addictive treatments.
A new study reveals that COVID-19 variants are formed in chronic patients with weakened immune systems, who experience prolonged infections. This leads to the accumulation of mutations, similar to those found in severe illness variants.
A new method using the Vortex fluidic device can test hundreds of proteins in under 5 minutes, with data readable by a cell phone camera. This technology has the potential to improve diagnosis and treatment of diseases in remote areas, reducing mortality and morbidity.
A novel staging framework assesses Huntington's Disease progression and enables early-stage clinical trials of drugs. The HD-ISS groups patients by biological, clinical, and functional characteristics, allowing researchers to evaluate therapeutics in the earliest stages of disease.
Researchers at Chalmers University of Technology have invented a material that uses electrical signals to separate biomolecules, paving the way for efficient production of biomedicines. The material's ability to function in biological fluids with buffering capacity enables remote-controlled drug release and reduces energy consumption.
A team of researchers has determined the cryo-electron microscopy structures of three NPY receptors in complex with the peptide ligand and Gi protein. The study reveals interaction details between different NPY receptors and the peptide, highlighting distinct conformations upon binding to each receptor. This understanding is crucial fo...
A University of Waterloo study found that current Hepatitis B vaccination, screening, and treatment strategies in Ontario would leave the province short of its goal to reduce preventable infections. The report's authors developed a computer model simulating long-term effects of existing strategies, which they found would only decrease ...
A research team from Tokyo University of Science has developed a new method to create copolymers with different metal species, which have potential uses in catalysis and drug discovery. The technique allows for controlling the composition of metal species in the resulting polymer.
Researchers have developed a new probe to detect Alzheimer's disease biomarkers using near-infrared fluorescence, which may help diagnose the disease early and prevent its progression. The probe binds oligomeric Aβ proteins, a hallmark of Alzheimer's disease, offering a potential alternative to existing treatments.
Researchers developed an antibody cocktail effective against a Hendra virus variant, neutralizing its ability to mutate and evade recognition. The combination of four antibodies leaves the virus with minimal ability to further evolve, providing significant protection against this global biosecurity threat.
A new EU project, DeLIVERY, aims to develop a microscopy system for liver cells to test tolerability of drug interactions. The system will enable researchers to observe how liver cells react to different medications, dosages, and combinations, potentially leading to improved patient safety.
A UVA researcher is using a harmless amoeba to develop an innovative treatment for deadly C. difficile infections in young children. The approach has the potential to deliver specific antibodies directly to the gut, reducing the need for antibiotics and addressing a growing public health threat.
Researchers from China have developed a novel bioconjugate that can suppress the growth of K-Ras mutant pancreatic tumors. The conjugate, which targets folate receptors and macropinocytosis, was found to be highly cytotoxic and effective at suppressing tumor growth.
Researchers have identified new biomarkers to detect non-small cell lung cancer in its early stages through a blood test, offering improved survival chances. The approach can also identify potential drug resistance, allowing clinicians to choose alternative treatment options.
Pharmaceutical scientist Hans Lennernäs will collaborate with JGU's Peter Langguth to investigate ways to mitigate chemotherapy side effects. The goal is to identify active substances that can counteract adverse reactions and develop effective drugs.
Researchers from Brigham and Women's Hospital and MIT designed an oil-based gel system, oleogel, to deliver medications to children with swallowing difficulties. The system has been shown to be compatible with most drugs and can facilitate drug uptake at levels comparable to solid tablets.
A new interactive web portal, SpUR, catalogues over 1,000 splicing events found in cancers, highlighting their role in tumor development and progression. The database provides a platform for researchers to study RNA dysregulations in cancer and develop RNA-based anti-cancer drugs.
New data analyses from RedHill's Talicia H. pylori eradication clinical trials program showed high eradication rates and favorable safety and efficacy profiles in patients with diabetes. The study found that Talicia maintained high eradication rates of 91.7% and 84.1% in patients with and without diabetes, respectively.
A new study found that vaccinated people with mild breakthrough COVID-19 infections can experience debilitating long COVID symptoms. Vaccination reduced the risk of death by 34% and long COVID by 15%, but not all manifestations were prevented. Researchers emphasize the need for additional layers of protection to mitigate risks.
Researchers at Keck School of Medicine of USC are testing the efficacy of 3K3A-APC as a cerebroprotectant to reduce brain bleeds in acute ischemic stroke patients. The experimental drug has shown promising results in Phase 2 clinical trials, reducing incidence of brain hemorrhage by nearly 20%.
The University of Minnesota has received a $66 million grant from the NIAID to establish a center for developing antiviral drugs for pandemic-level viruses, including SARS-CoV-2. The Midwest Antiviral Drug Discovery Center will bring together investigators from the University and sixteen other institutions nationwide.
The US Army Medical Research Institute of Infectious Diseases has made a breakthrough in understanding Crimean-Congo hemorrhagic fever virus (CCHFV) disease process. The study found that the host inflammatory response is a significant driver of CCHFV-mediated disease, and that modulating this response could help prevent severe disease....
A new review highlights the risks of fatty liver disease caused by metabolic dysfunction, characterized by fat accumulation in liver cells and oxidative stress. The progression of the disease can lead to inflammation, fibrosis, and cirrhosis with a high risk of hepatocellular carcinoma.
A team of scientists led by Professor Barbara Pierscionek has made significant progress in developing an anti-cataract drug. Lab trials showed improvement in refractive index profiles and lens opacity in 61% and 46% of cases, respectively.
A team of researchers has successfully treated damaged pig hearts with cardiac progenitor cells, demonstrating the formation of new cardiac tissue and improved cardiac function. The treatment could potentially be used to treat patients with serious heart failure, particularly older patients with coexisting conditions.
Researchers developed an algorithm to quickly identify two cancer drugs that work well together, reducing testing time from three years to eight weeks. The new method uses gene expression data to prioritize potential combinations and has been confirmed in lab tests.
Researchers revived photoreceptor cells in human macula, responding to bright and dim lights. The study restores communication between retinal cells, transforming brain and vision research.
A study published in JCI Insight reveals that epigenetic drugs targeting BRD4 significantly reduce scarring in patients with scleroderma. The findings could lead to repurposing these drugs for faster relief from debilitating symptoms of this chronic disease.
Researchers found phosphatidylinositol bisphosphate (PIP2) essential for epithelial cell-cell adhesion and maintaining cellular identity. PIP2 regulates epithelial properties by recruiting Par3 to the plasma membrane, facilitating the formation of adherens junctions and preventing epithelial-mesenchymal transformation.